Article    Table of Contents                    Full Text of this article Free    PDF of this article (PDFs free after 6 months)    Summary for Patients    Summary for Patients (PDF)    Figures/Tables List    Related articles in Annals  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Chou, R.    Helfand, M.    Related Articles in PubMed    PubMed Citation    PubMed

CLINICAL GUIDELINES

Screening for Hepatitis C Virus Infection: A Review of the Evidence for the U.S. Preventive Services Task Force

Roger Chou, MD; Elizabeth C. Clark, MD, MPH; and Mark Helfand, MD, MPH

16 March 2004 | Volume 140 Issue 6 | Pages 465-479

Background: Hepatitis C virus (HCV) is the most common bloodborne pathogen in the United States and is an important cause of patient morbidity and mortality, but it is unclear whether screening to identify asymptomatic infected persons is appropriate.

Purpose: To synthesize the evidence on risks and benefits of screening for HCV infection.

Data Sources: MEDLINE (through February 2003), Cochrane Clinical Trials Registry (2002, Issue 2), reference lists, and experts.

Study Selection: Controlled studies of screening and antiviral therapy and observational studies on other interventions, risk factors, accuracy of antibody testing, work-up, harms of biopsy, and long-term outcomes.

Data Extraction: Using preset criteria, the authors assessed the quality of included studies and abstracted information about settings, patients, interventions, and outcomes.

Data Synthesis: There are no published trials of screening for HCV infection. Approximately 2% of U.S. adults have HCV antibodies, with the majority having chronic infection. Risk factor assessment could identify adults at substantially higher risk. Antiviral treatment can result in a sustained virologic response rate of 54% to 56%, but no trials have been done specifically in asymptomatic patients likely to be identified by screening. Data are insufficient to determine whether treatment improves long-term outcomes. There are no data to estimate the benefit from counseling or immunizations. Although risks of biopsy and treatment appear minimal or self-limited, data on other adverse effects of screening, such as labeling or anxiety, are sparse.

Conclusions: Antiviral treatment can successfully eradicate HCV, but data on long-term outcomes in populations likely to be identified by screening are lacking. Although the yield from targeted screening, particularly in intravenous drug users, would be substantially higher than in the general population, data are inadequate to accurately weigh the overall benefits and risks of screening in otherwise healthy asymptomatic adults.

Author and Article Information

From Oregon Health & Science University and the Veterans Affairs Medical Center, Portland, Oregon.

Disclaimer: The authors of this article are responsible for its contents, including any clinical or treatment recommendations. No statement in this article should be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.

Acknowledgments: The authors thank Susan Wingenfeld and Kathryn Pyle Krages, AMLS, MA, for administrative support, and Heidi Nelson, MD, MPH, for reviewing the manuscript.

Grant Support: This study was conducted by the Oregon Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality, Contract #290-97-0018, Task Order No. 2, for the U.S. Preventive Services Task Force.

Potential Financial Conflicts of Interests: None disclosed.

Requests for Single Reprints: Reprints are available from the Agency for Healthcare Research and Quality Web site (http://www.preventiveservices.ahrq.gov) and through the Agency for Healthcare Research and Quality Publications Clearinghouse (telephone, 800-358-9295).

Current Author Addresses: Drs. Chou and Helfand: Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Mailcode BICC, Portland, OR 97239.

Dr. Clark: University of Iowa College of Medicine, 200 Hawkins Drive, 01293-F PFP, Iowa City, IA 52242-1097.

Related articles in Annals:

Clinical Guidelines
Screening for Hepatitis C Virus Infection in Adults: Recommendation Statement
U.S. Preventive Services Task Force*

Annals 2004 140: 462-464. [ABSTRACT][SUMMARY][Full Text]  

Summaries for Patients
Screening for Hepatitis C Virus Infection: Recommendations from the U.S. Preventive Services Task Force

Annals 2004 140: I-62. [Full Text]  

Letters
Screening for Hepatitis C Virus Infection in Adults
Josiah D. Rich, Lynn E. Taylor, AND Scott A. Allen

Annals 2004 141: 575-576. [Full Text]  

Letters
Screening for Hepatitis C Virus Infection in Adults
Ned Calonge AND Janet D. Allan

Annals 2004 141: 576. [Full Text]  

This article has been cited by other articles:

				B. J. Veldt, E. J. Heathcote, H. Wedemeyer, J. Reichen, W. P. Hofmann, S. Zeuzem, M. P. Manns, B. E. Hansen, S. W. Schalm, and H. L.A. Janssen Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis Ann Intern Med, November 20, 2007; 147(10): 677 - 684. [Abstract] [Full Text] [PDF]

				F. Sahajian, P. Vanhems, F. Bailly, J. Fabry, C. Trepo, M. Sepetjan, and Members of ADHEC Screening campaign of hepatitis C among underprivileged people consulting in health centres of Lyon area, France Eur J Public Health, June 1, 2007; 17(3): 263 - 271. [Abstract] [Full Text] [PDF]

				M. A. Rifai Ethical Impasses in the Care of Patients With Hepatitis C Psychosomatics, December 1, 2006; 47(6): 540 - 541. [Full Text] [PDF]

				M. A. Rifai, J. K. Moles, L. P. Lehman, and B. J. Van der Linden Hepatitis C screening and treatment outcomes in patients with substance use/dependence disorders. Psychosomatics, March 1, 2006; 47(2): 112 - 121. [Abstract] [Full Text] [PDF]

				T. Wong and S. S. Lee Hepatitis C: a review for primary care physicians Can. Med. Assoc. J., February 28, 2006; 174(5): 649 - 659. [Abstract] [Full Text] [PDF]

				M. T. Nguyen, S. K. Herrine, C. A. Laine, K. Ruth, and D. S. Weinberg Description of a New Hepatitis C Risk Assessment Tool Arch Intern Med, September 26, 2005; 165(17): 2013 - 2018. [Abstract] [Full Text] [PDF]

				P. L. Santaguida, M. Helfand, and P. Raina Challenges in Systematic Reviews That Evaluate Drug Efficacy or Effectiveness Ann Intern Med, June 21, 2005; 142(12_Part_2): 1066 - 1072. [Abstract] [Full Text] [PDF]

				M. A. Rifai and D. L. Rosenstein Hepatitis C and Psychiatry Focus, April 1, 2005; 3(2): 194 - 202. [Abstract] [Full Text] [PDF]

				M. J. Alter, L. B. Seeff, B. R. Bacon, D. L. Thomas, M. O. Rigsby, and A. M. Di Bisceglie Testing for Hepatitis C Virus Infection Should Be Routine for Persons at Increased Risk for Infection Ann Intern Med, November 2, 2004; 141(9): 715 - 717. [Abstract] [Full Text] [PDF]

				N. Calonge and G. Randhawa The Meaning of the U.S. Preventive Services Task Force Grade I Recommendation: Screening for Hepatitis C Virus Infection Ann Intern Med, November 2, 2004; 141(9): 718 - 719. [Abstract] [Full Text] [PDF]

				J. D. Rich, L. E. Taylor, and S. A. Allen Screening for Hepatitis C Virus Infection in Adults Ann Intern Med, October 5, 2004; 141(7): 575 - 576. [Full Text] [PDF]

				J. D. Matthews and E. J. Bini Epidemiology, Diagnosis, and Treatment of Chronic Hepatitis C Journal of Pharmacy Practice, August 1, 2004; 17(4): 229 - 238. [Abstract] [PDF]

				USPSTF Recommends Against Screening for HCV Infection Journal Watch Gastroenterology, March 30, 2004; 2004(330): 8 - 8. [Full Text]

				USPSTF Recommends Against Screening for HCV Infection Journal Watch (General), March 26, 2004; 2004(326): 1 - 1. [Full Text]